149 results about "Lipid vesicle" patented technology

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.

Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation.

Sparingly water-soluble agents can be formulated as cyclodextrin complexes, however, these water-soluble drug-cyclodextrin complexes dissociate when the complex is administered into patients. The dilution of the complex in the patient leads to the drug being released from the complex, so the drug is not effectively targeted. In contrast, drugs encapsulated in the aqueous core of a lipid vesicles are not released when the liposome is diluted in blood. This invention describes compositions and methods whereby cyclodextrin or polyanionic beta-cyclodextrin drug-complexes are mixed with a preformed liposome containing the amine salts of an acidic compound. This results in the drug cyclodextrin complex being transferred into the liposome where it is stably retained. The liposome-encapsulated drug can then be injected into a patient.

A cosmetic treatment process is provided herein useful for reducing fine lines, wrinkles, or fine lines and wrinkles. The process comprises contacting a composition to an area of the skin or tissue of a subject, wherein the composition comprises a substance encapsulated within a lipid vesicle comprising a lipid having one or more polyethylene glycol (PEG) chains. The lipid vesicle has a charged surface, and an electric voltage is applied directly to the area of the skin that is contacted with the composition, whereby fine lines, wrinkles, or fine lines and wrinkles are reduced.

The invention provides an anti-aging co-transport nano lipid vesicle and a preparation method and application thereof, and belongs to the technical field of functional cosmetics. The anti-aging co-transport nano lipid vesicle comprises the following components in parts by weight: 0.02-32 parts of an anti-aging active component, 11.1-65 parts of a nano lipid vesicle, and 3-88 parts of water, wherein the nano lipid vesicle comprises the following raw materials in parts by weight: 5.0-20.0 parts of a nonionic surfactant, 5.0-30.0 parts of water-soluble alcohol, 1.0-10.0 parts of compound phosphatide, and 0.1-5.0 parts of cholesterol; and the anti-aging active component includes a water insoluble anti-aging component and/ or a water soluble anti-aging component. According to the preparation method, the anti-aging active components are loaded in the same nano lipid vesicle, so that transdermal co-transport of multi-target-point anti-aging active components of various anti-aging mechanisms can be realized; and synergistic interaction is realized, and thus the anti-aging effect is improved.

A new formulation of dehydrated lipid vesicles employs a vesicle preserver and permits the control of release and delivery of active pharmaceutical ingredients into the respiratory system for treatment in particular of asthma. The typical formulation provides controlled release of the active pharmaceutical ingredient from 0% to 100% from 0 to 72 hours after inhalation, changes the systemic administration to topical administration, allows prolonged therapeutic period for one administration, increased stability, with reduced dose, reduced systemic side effects, reduced toxicity.

Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions, such as liposomes and other lipid vesicles, to the tympanic membrane. Medicaments useful for treating pain, inflammation or infection in the outer ear may be co-administered. If utilized for transmembrane administration, the liposomes or other lipid vesicles will usually not be sterically stabilized. The medicaments delivered according to the methods of the invention include antibiotic, anti-viral, anti-fungal and anti-inflammatory agents that are useful in treatment and/or prophylaxis of middle ear infections and their sequelae.

A phospholipid vesicle such as a virus is to be rapidly separated (concentrated, roughly purified) and good detection (diagnosis) results can be obtained with suppressing inhibition of virus-denature, PCR inhibition, latex-aggregation inhibition, and the like. Moreover, the above operations are to be automated. A phospholipid vesicle is separated using a water-soluble cationic magnetic fine particle by a composite formation through a covalent bond or physical adsorption of a substance having a cationic functional group, a substance having a hydroxyl group, and a substance having magnetism.

A hydrated lecithin carrier vesicle composition includes a lecithin-derived membrane-forming lipid vesicle in conditioned water for incorporation of an active ingredient to form a dispersed composition. A method of making the hydrated lecithin carrier vesicle includes using lecithin having not more than about 80% w/w phosphatidylcholine in the presence of conditioned water.

The preparation and use of a transducing polypeptide (TP)— lipid vesicle complex having a small proportion of positively charged (cationic) lipids in the make-up of the lipid vesicle, e.g., liposome, for safe and efficient intracellular delivery of therapeutic agents, such as proteins, DNA, small molecules and/or other drugs, into a cell of a higher organism, in vitro or in vivo is disclosed. The delivery system of the invention results in increased efficacy of intracellular delivery of such agents, bypassing the endocytotic pathway of intracellular delivery while at the same time minimizing the toxicity of the delivery system towards the recipient cells.

High-density arrays of attoliter volume elements can be created within minutes in a parallel and effortless manner by using self-assembly of nanometer-sized components (e.g., lipid vesicles containing (bio)chemicals) based on biological recognition. The ultrasmall volumes allow localization to a predefined position of a few or single molecules, and then screening for their (bio)chemical properties or performing confined (bio)chemical reactions.